Segments and Geographic Information (Tables)

12 Months Ended

Jan. 02, 2022

Segment Reporting [Abstract]

Net Revenue by Segment

Net revenue by segment is as follows:

	Fiscal Year Ended
	January 2, 2022		January 3, 2021		December 29, 2019
Americas	$	1,228.9	$	1,067.3	$	1,042.5
EMEA		276.3		240.6		251.5
Greater China		274.4		229.6		242.5
Other		263.2		228.7		265.0
Net revenue	$	2,042.8	$	1,766.2	$	1,801.5

Adjusted EBITDA by Segment

Adjusted EBITDA by segment is as follows:

	Fiscal Year Ended
	January 2, 2022			January 3, 2021
Americas	$	516.6		$	463.1
EMEA		63.9			41.9
Greater China		129.2			108.0
Other		79.9			65.9
Total Segment Adjusted EBITDA		789.6			678.8
Corporate (1)		(241.5	)		(230.4	)
Depreciation and amortization		(328.1	)		(325.9	)
Interest expense, net		(146.0	)		(198.2	)
Loss on extinguishment of debt		(50.3	)		(12.6	)
Stock-based compensation		(22.2	)		(8.6	)
Restructuring and severance-related costs		(8.2	)		(11.7	)
Arbitration award		7.4			—
Quidel acquisition-related costs		(7.0	)		—
Tax indemnification expense, net		(0.8	)		(31.2	)
Costs related to Ortho's initial public and secondary offerings		(5.4	)		(7.8	)
EU medical device regulation transition costs		(4.0	)		(4.3	)
Unrealized foreign currency exchange losses		—			(63.0	)
Other adjustments		(9.5	)		(10.5	)
Loss before provision for (benefit from) income taxes	$	(26.0	)	$	(225.3	)

(1) Corporate primarily consists of costs related to executive and staff functions, including certain finance, human resources, manufacturing, and information technology, which benefit the enterprise as a whole. These costs are primarily related to the general management of these functions on a corporate level and the design and development of programs, policies, and procedures that are then implemented in the individual segments, with each segment bearing its own cost of implementation. The Company’s Corporate function also includes debt and stock-based employee compensation expense associated with all employee stock-based awards.

Management EBITDA by Segment

Management EBITDA by segment for the fiscal year ended December 29, 2019 is as follows:

	Fiscal Year Ended
	December 29, 2019
Americas	$	418.4
EMEA		54.9
Greater China		118.4
Other		88.8
Total Segment Management EBITDA		680.5
Corporate (1)		(177.9	)
Depreciation and amortization		(327.5	)
Interest expense, net		(231.4	)
Stock-based compensation		(18.6	)
Restructuring and severance-related costs		(36.0	)
Tax indemnification expense, net		(29.2	)
EU medical device regulation transition costs		(3.2	)
Unrealized foreign currency exchange gains		19.6
Other adjustments		(35.2	)
Management adjustments and realized foreign exchange losses		(21.9	)
Loss before provision for (benefit from) income taxes	$	(180.8	)

(1) Corporate primarily consists of costs related to executive and staff functions, including certain finance, human resources, manufacturing, and information technology, which benefit the enterprise as a whole. These costs are primarily related to the general management of these functions on a corporate level and the design and development of programs, policies, and procedures that are then implemented in the individual segments, with each segment bearing its own cost of implementation. The Company’s Corporate function also includes debt and stock-based employee compensation expense associated with all employee stock-based awards.

Net revenues for the Company's country of domicile, countries with significant concentrations

Net revenues for the Company’s country of domicile, countries with significant concentrations, and all other countries were as follows:

	Fiscal Year Ended
	January 2, 2022		January 3, 2021		December 29, 2019
Net revenue
United Kingdom	$	27.5	$	21.9	$	19.9
United States		1,016.1		901.2		855.1
Greater China		274.4		229.6		242.5
Other countries		724.8		613.5		684.0
Total net revenue	$	2,042.8	$	1,766.2	$	1,801.5

Property, Plant and Equipment, Net and Right-Of-Use Assets For the Company's Country of Domicile

Property, plant and equipment, net and Right-of-use assets for the Company’s country of domicile, countries with significant concentrations, and all other countries were as follows:

	January 2, 2022		January 3, 2021
Long-lived assets
United Kingdom	$	107.2	$	105.6
United States		470.0		507.5
Other countries		244.5		245.6
Total long-lived assets	$	821.7	$	858.7